Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT01266395
Last Updated: 2011-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1268 participants
OBSERVATIONAL
2010-01-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient's Perception in Symptoms Related to Morning Activity Based on Chronic Obstructive Lung Disease
NCT00894426
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00722267
Observational Study On The Characterization Of 24-Hour Symptoms In Patients With COPD
NCT03105999
CorRELation Between PatIent PErception and Findings on Clinical Examination
NCT01627743
Perception of Symptom Variability in COPD
NCT01753427
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients of both sexes,\> 40 years.
* Patients diagnosed with COPD according to global consensus on the definition, classification and management of the disease (GOLD) criteria:
* post-bronchodilator forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) \<70%
* post-bronchodilator FEV1 \<80% (stage II, III and IV)
Exclusion Criteria
* Patient with other respiratory disease than COPD (eg bronchial asthma, cystic fibrosis, severe bronchiectasis, restrictive lung disease, cancer, etc.).
* Patients with mild COPD: FEV1\> 80%
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Vitoria-Gasteiz, Alava, Spain
Research Site
Elda, Alicante, Spain
Research Site
Petrel, Alicante, Spain
Research Site
Almería, Almeria, Spain
Research Site
Ávila, Avila, Spain
Research Site
Badajoz, Badajoz, Spain
Research Site
Inca, Balearic Islands, Spain
Research Site
Son Ferriol, Balearic Islands, Spain
Research Site
Barcelona, Barcelona, Spain
Research Site
El Hospitalet de Llobregat, Barcelona, Spain
Research Site
Puerto Real, CAdiz, Spain
Research Site
Castellon, Castellon, Spain
Research Site
Torreblanca, Castellon, Spain
Research Site
Vinaròs, Castellon, Spain
Research Site
Lucena, Cordoba, Spain
Research Site
Pea'arroya-pueblonuevo, Cordoba, Spain
Research Site
A Picota (mazaricos), Coruna, Spain
Research Site
Carballo (carballo), Coruna, Spain
Research Site
Ferrol, Coruna, Spain
Research Site
Santiago de Compostela, Coruna, Spain
Research Site
Guadalajara, Guadalajara, Spain
Research Site
Donostia / San Sebastian, Guipuzcoa, Spain
Research Site
Placencia de Las Armas-soraluz, Guipuzcoa, Spain
Research Site
Espelúy, Jaen, Spain
Research Site
Mures, Jaen, Spain
Research Site
Nájera, La Rioja, Spain
Research Site
Arguineguín, Las Palmas, Spain
Research Site
Abadin (casco Urbano), Lugo, Spain
Research Site
Baralla (casco Urbano), Lugo, Spain
Research Site
Lugo, Lugo, Spain
Research Site
Viveiro (casco Urbano), Lugo, Spain
Research Site
Alcalá de Henares, Madrid, Spain
Research Site
Alcorcón, Madrid, Spain
Research Site
Madrid, Madrid, Spain
Research Site
San Sebastián de los Reyes, Madrid, Spain
Research Site
Cieza, Murcia, Spain
Research Site
Murcia, Murcia, Spain
Research Site
Pamplona, Navarre, Spain
Research Site
Leiro (capital), Ourense, Spain
Research Site
Vigo, Pontevedra, Spain
Research Site
Arriondas, Principality of Asturias, Spain
Research Site
Cangas de Narcea, Principality of Asturias, Spain
Research Site
Jarrio, Principality of Asturias, Spain
Research Site
Oviedo, Principality of Asturias, Spain
Research Site
Dos Hermanas, Sevilla, Spain
Research Site
Seville, Sevilla, Spain
Research Site
Villanueva del Ariscal, Sevilla, Spain
Research Site
Benaguasil, Valencia, Spain
Research Site
Burjassot, Valencia, Spain
Research Site
La Pobla de Vallbona, Valencia, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Zaragoza, Zaragoza, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-RES-DUM-2010/2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.